The primary objective of the trial was assessment of antitumor effect of the therapy, and the secondary objectives were progression-free survival and overall survival, as well as proportion of patients disease free at six months, and safety and tolerability
Oncolytics Biotech Inc., of Calgary, Alberta, said it conducted an internal analysis of the blinded combined data for all 80 patients enrolled in the first stage of its Phase III study testing oncolytic virus Reolysin in combination with carboplatin and paclitaxel for the treatment of head and neck cancers, with data showing a greater than expected median evolving progression-free survival (PFS) of the 80 patients, which comprise the combined control and test groups
Pfizer Inc., of New York, reported that the combination of its Torisel (temsirolimus) and bevacizumab (Avastin, Genentech Inc.) failed to demonstrate superiority to bevacizumab plus interferon-alfa-2a in progression-free survival in the Phase III INTORACT trial
Genentech Inc., a South San Francisco-based member of the Roche Group, reported that Avastin (bevacizumab) plus radiation and temozolomide chemotherapy demonstrated a significant improvement in progression-free survival, a co-primary endpoint of the Phase III AVAglio study
The data showed that expression of four ICT-107 targeted antigens in pre-vaccine tumors was associated with median overall survival of 38.4 months and median progression-free survival of 16.9 months in newly diagnosed glioblastoma multiforme patients
Secondary endpoints include MMR at five years, MR at three months (a reduction in the level of Bcr-Abl transcripts to 10 percent or less), complete cytogenic response rate at 12 months, progression-free survival and overall survival
Apogenix GmbH, of Heidelberg, Germany, said its Phase II trial of lead compound APG101 in recurrent glioblastoma met and exceeded expectations, which was to increase the percentage of patients reaching progression-free survival for six months by 100 percent...Secondary endpoints include progression-free survival, overall survival and safety
The single-arm, open-label study of JX-594, administered weekly by intravenous infusions, will examine radiographic response rate based on modified RECIST and modified Choi criteria and will subsequently follow patients for progression-free survival and overall survival
The randomized trial, titled TaCTiCC (TroVax and Cyclophosphamide Treatment in Colorectal Cancer) will evaluate whether TroVax, administered alone or in combination with cyclophosphamide, is effective by assessing anti-5T4 immune responses, in addition to secondary measures of clinical benefit, including progression-free survival, objective response rate and overall survival
The primary endpoint is progression-free survival (PFS) at nine months, while secondary endpoints include PFS at one year and overall survival at one year
A total of 450 patients will be enrolled, and additional endpoints include overall response, immune response, progression-free survival and safety...Secondary endpoints include progression-free survival, tumor response and pharmacokinetics
The primary objective of the trial was assessment of antitumor effect of the therapy, and the secondary objectives were progression-free survival and overall survival, as well as proportion of patients disease free at six months, and safety and tolerability